CLINICAL ADVISORY BOARD

 

Chair: Robert W. Holloway, MD
Medical Director, Gynecologic Oncology, AdventHealth Cancer Institute, Orlando, Florida

Dr. Holloway is the principal investigator for VIRO-15 and has served on several committees of SGO, including its Board of Directors.  Dr. Holloway has authored or coauthored more than 100 peer-reviewed articles.  He is a Fellow of the American College of Surgeons and founding member of the Global Robotics Institute at AdventHealth, Orlando.  Dr. Holloway completed medical school at Vanderbilt University Medical Center, residency at University of Alabama, Birmingham, and fellowship at Georgetown University Hospital.

 

Robert L. Coleman, MD
Gynecologic Oncology, Chief Scientific Officer, US Oncology Research, The Woodlands, Texas

Dr. Coleman currently serves on the Board of Directors of Gynecologic Oncology Group and is a Director of GOG-Partners.  In addition, he has served as President of SGO and as a Council member and Secretary Treasurer for the International Gynecologic Cancer Society, for which he is President-Elect (2020-2022). Dr. Coleman has authored or coauthored more than 300 peer-reviewed articles. Dr. Coleman completed medical school at Creighton University School of Medicine, residency at Northwestern University Medical Center, and gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. He served as Professor and Ann Rife Chair in Gynecology at University of Texas, M.D. Anderson Cancer Center and Executive Director, M.D. Anderson Cancer Network Research until April 2020.

 

Thomas J. Herzog, MD
Deputy Director of the University of Cincinnati Cancer Institute and Vice-Chair of Quality and Safety for Obstetrics and Gynecology, University of Cincinnati College of Medicine Cincinnati, Ohio

Dr. Herzog is Secretary Treasurer and Associate Director of the GOG-Foundation.  In addition, he has served on the leadership board or council of SGO, the Foundation for Women’s Cancer, Board of Governors for the American College of Surgeons, American Board of Obstetrics and Gynecology, International Gynecologic Cancer Society.  Dr. Herzog has authored/co-authored 290+ peer-reviewed articles.  Dr. Herzog graduated from the University of Cincinnati College of Medicine and completed his residency at Good Samaritan Hospital in Cincinnati and a fellowship in gynecologic oncology at the Washington University School of Medicine, St. Louis, MO.

 

Alberto A. Mendivil, MD
Co-Director, Gynecologic Oncology, Hoag Memorial Hospital Presbyterian, Newport Beach, California

Dr. Mendivil, site principal investigator for VIRO-15, serves as Co-Director, Gynecologic Oncology and Complex Pelvic Surgery, Hoag Hospital.  Dr. Mendivil has authored or coauthored more than 40 peer-reviewed publications and has been the principal investigator or site sub-investigator on 20+ clinical trials. Dr. Mendivil received his medical degree from the University of Utah School of Medicine and completed internship and residency training in Obstetrics and Gynecology at the University of California, Irvine, and fellowship training in gynecologic oncology at the University of North Carolina, Chapel Hill.

 

David M. O’Malley, MD
Professor and Division Director, Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Columbus, Ohio

Dr. O’Malley is the clinical trial advisor/lead for ovarian cancer within GOG Partners, a committee member for the NCI Gynecologic Cancer Steering Committee’s Ovarian Task Force and the NRG Oncology (Ovarian Cancer and Developmental Therapeutics Groups), and a panel member of the national Comprehensive Cancer Network Guidelines for Ovarian Cancer.  Dr. O’Malley has authored 130+ peer-reviewed publications.  Dr. O’Malley received his medical degree from the Wayne State University School of Medicine, and completed his residency at Case Western Reserve University (MetroHealth) and the Cleveland Clinic Foundation, and gynecologic oncology fellowship at Yale University.